Literature DB >> 18186175

Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment.

Jun-Feng Wang1.   

Abstract

OBJECTIVE: Converging lines of evidence indicate that defects in the mitochondrial electron transport chain (ETC) are associated with bipolar disorder (BD), and that mood-stabilizing drugs produce neuroprotective effects. Our objective is to review the most recent findings regarding this research.
METHOD: We searched MEDLINE and have reviewed here the most recently published articles.
RESULTS: There are deletions, mutation, and decreased expression of mitochondrial ETC complexes in BD. Because ETC is a major source of reactive oxygen species, these factors, along with decreased expression of antioxidant enzymes in BD, suggest the presence of oxidative damage in this disorder. Numerous recent studies have shown that mood-stabilizing drugs produce neuroprotective effects against oxidative damage and increase expression and activities of endogenous antioxidant enzymes in the rat brain.
CONCLUSION: These findings indicate that the process of oxidative damage could be a significant therapeutic target for the treatment of BD with mood-stabilizing drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18186175     DOI: 10.1177/070674370705201202

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  15 in total

1.  Physical Exercise for Treatment of Mood Disorders: A Critical Review.

Authors:  C M Hearing; W C Chang; K L Szuhany; T Deckersbach; A A Nierenberg; L G Sylvia
Journal:  Curr Behav Neurosci Rep       Date:  2016-10-14

Review 2.  Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential.

Authors:  Ines Batinić-Haberle; Júlio S Rebouças; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

3.  Lithium, inositol and mitochondria.

Authors:  Lilach Toker; Galila Agam
Journal:  ACS Chem Neurosci       Date:  2014-06-02       Impact factor: 4.418

4.  Association study on the mitochondrial gene NDUFV2 and bipolar disorder in the Chinese Han population.

Authors:  Jing Zhang; Xingwang Li; Yang Wang; Jue Ji; Fengping Yang; Guoyin Feng; Peng Wan; Klaus Lindpaintner; Lin He; Guang He
Journal:  J Neural Transm (Vienna)       Date:  2009-02-05       Impact factor: 3.575

5.  Evaluation of mitochondrial dysfunction due to oxidative stress in therapeutic, toxic and lethal concentrations of tramadol.

Authors:  Leila Mohammadnejad; Kambiz Soltaninejad; Mohammad Seyedabadi; Seyed Khosro Ghasem Pouri; Mohammad Shokrzadeh; Hamidreza Mohammadi
Journal:  Toxicol Res (Camb)       Date:  2021-11-08       Impact factor: 3.524

6.  Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

Authors:  Richard Scott Jope
Journal:  Front Mol Neurosci       Date:  2011-08-09       Impact factor: 5.639

Review 7.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

Review 8.  Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders.

Authors:  Stefano Puglisi-Allegra; Stefano Ruggieri; Francesco Fornai
Journal:  Transl Psychiatry       Date:  2021-07-05       Impact factor: 6.222

9.  Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Bipolar Disorder Normalizes after Zinc and Anti-oxidant Therapy.

Authors:  A J Russo
Journal:  Nutr Metab Insights       Date:  2010-10-19

10.  The functional role of MnSOD as a biomarker of human diseases and therapeutic potential of a new isoform of a human recombinant MnSOD.

Authors:  Antonella Borrelli; Antonietta Schiattarella; Patrizia Bonelli; Franca Maria Tuccillo; Franco Maria Buonaguro; Aldo Mancini
Journal:  Biomed Res Int       Date:  2014-01-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.